Israeli biotech company Evogene Ltd. and U.S.-based ELEO Inc. have announced a strategic collaboration to develop next-generation oral small-molecule inhibitors targeting the PCSK9 pathway, a clinically validated mechanism for reducing low-density lipoprotein cholesterol and managing cardiovascular disease risk. The partnership signals a growing industry push to move beyond injectable PCSK9 therapies toward convenient, pill-based alternatives that could dramatically expand patient access and market reach. As detailed in a PR Newswire announcement, the two companies intend to combine Evogene’s computational biology capabilities with ELEO’s drug development expertise to advance candidates targeting hyperlipidemia and related cardiovascular conditions.

The announcement places both companies in a competitive segment of the cardiovascular drug market at a time when demand for more accessible lipid-lowering therapies is intensifying. Cardiovascular disease remains the leading cause of death globally, accounting for an estimated 17.9 million deaths annually according to the World Health Organization, and hyperlipidemia is among the most prevalent modifiable risk factors driving that toll. The Alebund trial milestone in kidney disease earlier this year illustrated how specialty pharma partnerships are increasingly targeting chronic conditions where existing treatments leave significant gaps.

Why the PCSK9 Pathway Matters for Drug Development

PCSK9 inhibitors work by blocking a protein that degrades LDL receptors in the liver, effectively allowing the body to clear more harmful cholesterol from the bloodstream. The first approved agents in this class — injectable monoclonal antibodies including alirocumab and evolocumab — demonstrated LDL reductions of up to 60 percent in clinical studies and have shown meaningful cardiovascular outcome benefits. However, their high cost, which historically exceeded $14,000 annually per patient in the United States before payer negotiations, and their injectable delivery format have limited uptake to a fraction of eligible patients.

The oral small-molecule approach that Evogene and ELEO are pursuing represents the next competitive frontier in this space. Several large pharmaceutical companies, including Merck and Novo Nordisk, are already running clinical-stage programs targeting oral PCSK9 inhibition, making the field both commercially validated and intensely competitive. Evogene’s differentiated angle is its proprietary computational platform, which the company describes as capable of accelerating candidate identification by simulating biological interactions at scale before committing resources to laboratory synthesis and testing. For ELEO, partnering with a computationally driven discovery engine reduces early-stage attrition risk, one of the most costly phases of pharmaceutical development.

Strategic Fit and Commercial Implications

Evogene, listed on the Tel Aviv Stock Exchange and on Nasdaq under the ticker EVGN, has structured its business around licensing its computational biology platform across multiple therapeutic and agricultural domains. The collaboration with ELEO represents an extension of that model into cardiovascular medicine, a therapeutic category with a global market for lipid-lowering drugs valued in the tens of billions of dollars annually. A successful oral PCSK9 agent could command premium pricing while also attracting significantly broader prescription volumes than current injectables, given prescriber and patient preference for oral dosing.

ELEO Inc., a clinical-stage company focused on metabolic and cardiovascular diseases, brings drug development infrastructure and regulatory experience to the partnership. While specific financial terms of the collaboration — including any upfront payments, milestone structures, or royalty arrangements — were not disclosed in the announcement, such deals in early-stage biotech typically involve tiered milestone payments that can reach hundreds of millions of dollars if candidates progress through pivotal trials and gain regulatory approval. The collaboration’s focus on the PCSK9 pathway also aligns with broader market trends, as payers and health systems continue to prioritize cost-effective cardiovascular risk reduction at scale. Investors in both companies will be watching closely for data on candidate identification timelines and any signals regarding a progression toward formal preclinical or clinical studies. The partnership reflects a wider pattern of smaller biotech firms pooling computational and translational capabilities to compete in areas once dominated by large pharmaceutical incumbents, a dynamic increasingly visible across the sector as drug discovery costs escalate and timelines shorten under competitive pressure. For Evogene in particular, the deal adds a high-profile cardiovascular application to a platform portfolio that spans oncology, infectious disease, and agriculture, reinforcing the company’s strategy of monetizing its core technology across diverse end markets.